[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Resident's Forum
May 2012

Glycolipid Antigens for Treating Hepatic Colorectal Cancer Metastases and Their Effect on the Therapeutic Efficacy of Live Attenuated Listeria monocytogenes

Author Affiliations

Author Affiliations: Departments of Surgery (Drs Olino, Edil, Schulick, Yoshimura, and Weber) and Oncology (Drs Olino, Edil, Pardoll, Schulick, Yoshimura, and Weber, and Mss Meckel, Pan, and Thuluvath), Division of Immunology and Hematopoiesis, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland; and Department of Surgery, University Hospital of Basel, Basel, Switzerland (Dr Weber).

Arch Surg. 2012;147(5):480-482. doi:10.1001/archsurg.2011.2206
Abstract

Previous work demonstrated that a subset of natural killer T cells in mice decreased the antitumor efficacy of live attenuated Listeria monocytogenes where the actin A and internalin B genes were genetically deleted (LMD) against murine hepatic colorectal cancer metastases. Therefore, we hypothesized that the use of specific glycolipids known to selectively stimulate natural killer T-cell subsets used alone or co-administered with LMD would increase survival. We found that early or multiple administrations of glycolipids after tumor challenge had a strong impact on survival with or without LMD. Solitary administration or treatment given later was less efficacious but still showed a strong trend toward enhancing the antitumor activity of LMD. These results underscore the potential of glycolipids in the treatment of hepatic metastases and encourage further investigations into the immunomodulation of natural killer T cells to enhance the antitumor activity of LMD.

×